Our Story
WHAT IS THE
WORLD VETERINARY VACCINE CONGRESS?
Now in its 6th year the World Veterinary Vaccine Congress continues to bring experts from the global animal health industry to discuss scientific, regulatory and commercial issues affecting the veterinary biologics sector.
The four-day event will feature workshops, presentations, roundtable discussions and panels on:
• Funding & Investment for Animal Health
• One Health
• AMR
• Veterinary Immunology
• Vaccine Technology
• Vaccine Delivery
• Manufacturing
• Biotherapeutics for Companion Animal Diseases
Co-located with the World Vaccine Congress Europe, we have over 20 years’ experience in the human and veterinary biologics industry. This holistic approach between human and vet, helps accelerate research & development and collaboration in key areas such as; Innovation, Zoonotic & Transboundary Diseases, Technology Platforms, Vaccines, Clinical Models, Adjuvants & Immunotherapy.
With 800+ potential customers in attendance there will be an abundance of opportunities for making contacts with professionals, looking for solutions to challenges around the commercial and scientific issues in:
We bring about faster, more cost-effective and more efficacious cancer therapies, through executive level commentary, case studies and real time analysis from key stakeholders.
EVENT FORMAT
CO-LOCATED WITH
CONFERENCE TRACKS
FROM STRENGTH TO STRENGTH
The World Vaccine Congress Europe & it's co-conferences has gone from strength to strength and has experienced fantastic growth. 2020 will be an unmissable edition where 800+ industry professionals will join us in Barcelona.
From 2018-2019
companies up
300%
numbers up
225%
meetings up
250%
numbers up
175%
WHY NOW?
DISEASE X
Threatened by infectious diseases and the unknown, it’s more important than ever to unite every stakeholder from policy makers in government, HTA/payers, healthcare professionals, academic scientists to manufacturers and new SMEs to challenge the existing vaccine lifecycle model, at the biggest and most established European vaccine meeting.
ONE HEALTH
It is imperative for synergy between human and animal health to combat emerging zoonotic & transboundary diseases. The One Health holistic approach helps accelerate research & development and collaboration between human and animal health in key areas such as; Innovation, Zoonotic & Transboundary Diseases, Technology Platforms, Vaccines, Clinical Models, Adjuvants & Immunotherapy.
IMMUNO-ONCOLOGY
There is significant crossover between infectious disease and cancer when it comes to immune characterisation, interplay with T/B cells, multifaceted technology platforms, vaccine & antibody design. Join us as we discuss the importance of a united approach to advance infectious disease & cancer treatment. Regardless of whether your concerns are with the aging population, the young or the neglected, we cover such a broad scope of topics and diseases at such depth, that you’ll leave satisfied that you spent an incredibly productive few days with us.
CATALONIA IS A GREAT PLACE FOR INTERNATIONAL PHARMACEUTICAL COMPANIES
-
2017 saw
125
Pharma companies in Catalonia
-
Catalonia concentrated
71.6%
of Spanish pharmaceutical turnover (2017) and
43.7%
of Spanish pharmaceutical exports (2016)
-
Catalonia is the
birthplace
of pharmaceuticals in Spain and home to the
five biggest
Spanish Pharmaceutical companies
- R&D spending of Catalan pharmaceutical industry accounts for 32.1% of total Catalan industry spending in R&D
Organiser
